Dog trials slip Pro Bono's 'bonkers' subQ blood factors into lead
This article was originally published in Scrip
Pro Bono Bio has unveiled preclinical results that have raised its hopes of bringing to market within four years blood factor products for haemophilia patients that offer improvements over existing products on four fronts: duration of action, mode of administration, evenness of circulating dose and, in the case of Factor VIIa, possibility of prophylactic use for the first time.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.